Welcome to DaHao International Login Register
2022 Wuhan Cell Industry Conference and the 10th Wuhan Cell and Tumor Precision Medical Summit Forum
Industry:

Biology / Medicine / Health

Cycle:

Once a year

Time:

2022/11/19 - 11/20 (Sat To Sun Total 2 Days)    Error Correction

Address:

Hubei Wuhan International Expo Center ChinaHubei provinceWuhanHanyang District No. 619, Yingwu Avenue, Hanyang District, Wuhan

Sponsor:

Shanghai Shunzhan Exhibition Service Co., Ltd

Organizer:

Shanghai Shunzhan Exhibition Service Co., Ltd

Co-organizer:

Shanghai Shunzhan Exhibition Service Co., Ltd

Closed

INTRODUCTION

2022武汉细胞产业大会暨第十届武汉细胞与肿瘤精准医疗高峰论坛-大号会展 www.dahaoexpo.com

2022 Wuhan Cell Industry Conference and the 10th Wuhan Cell and Tumor Precision Medical Summit Forum

Wuhan Biopharmaceutical Innovation and Development Summit

Time: November 19-20, 2022 Place: Wuhan, China

Organizational structure (proposed):

Precision Medicine and Tumor MDT Professional Committee of Chinese Academy of Research Hospitals

Cell Therapy Industry and Clinical Research Branch of National Health Industry Enterprise Management Association

China Cancer Prevention and Treatment Alliance

Beijing Society for Accurate Diagnosis of Tumor Pathology

Zhongyuan Association for Pathological Diagnosis of Tumor

Jiangsu Biotechnology Association

Shenzhen Life Science Industry Association

Shenzhen Cell Therapy Technology Association

Shenzhen Life Technology Industry University Research Investment Alliance

Shenzhen Biomedical Promotion Association

Wuhan East Lake National Independent Innovation Demonstration Zone Biomedical Industry Association

Shanghai Laboratory Equipment Association

Shanghai Shunzhan Exhibition Service Co., Ltd

Introduction:

In recent years, modern biotechnology represented by genetic engineering and cell engineering has developed rapidly, major technologies such as the Human Genome Project have made breakthroughs, and the industrialization of biomedicine has accelerated significantly. With the favorable support of the national policy on innovative drugs, China's biomedical R&D investment will also continue to increase. As one of China's strategic emerging industries, the biopharmaceutical industry has developed rapidly and accumulated tremendous momentum. In drug development, the verified target/structure/indication has become a red sea, and the "inner roll" of the industry will become a shackle. Only the source innovation can break through the tight encirclement. Since the development of the biomedical industry, it has entered the clinical stage by a big step. In the face of the transformation trend of more and more pharmaceutical enterprises simultaneously laying out "large and small molecules", innovative large and small molecule drugs are both guided by clinical value and aim to meet the clinical needs of patients who have not been met. The global biopharmaceutical market shows a strong growth trend that is far faster than the global economic growth rate. The biopharmaceutical industry is ushering in a golden age of development driven by both technological progress and demand growth. Especially since the COVID-19, the global public health system has faced unprecedented challenges. Countries have increased their deployment of biomedicine, while increasing R&D investment for infectious diseases. China has made remarkable achievements in the prevention and control of this epidemic, which has further promoted the rapid development of the domestic biomedical industry.

2022 Cell Industry Conference The 10th (Wuhan) Cell and Tumor Precision Medical Summit Forum 2022 and Wuhan Biomedical Innovation and Development Summit will be held in Wuhan in November. This summit will set up exhibition areas and multiple sub forums, closely focusing on topics such as cell therapy research and development and industrialization, autoimmunity and tumor immunity, gene therapy and oncolytic virus, innovative drug development and technological innovation, antibody drug development and target screening, A number of authoritative experts and industry leaders from the national drug evaluation and supervision institutions, scientific research institutes, medical institutions, innovative pharmaceutical enterprises, bio therapy, biotechnology and service enterprises, upstream and downstream enterprises of the industrial chain, industrial parks, investment institutions, industry associations, etc. are specially invited to share and discuss, so as to promote the full speed development of the industry.

Who will sponsor

Preclinical cell research and clinical application transformation, cell storage and treatment, tumor immunotherapy, cell and gene therapy, investment strategy of biological innovative drug industry, frontier technology of biological innovative drugs, CDMO production process of biological drugs, preclinical research and registration application of biological drugs, single cell multiomics, single cell sequencing, isolation and detection of extracellular vesicles, gene therapy and oncolytic virus, solid tumor treatment and drug development TIL cell therapy, CAR-T/TCR-T cell therapy, universal CAR-T cell immunotherapy γδ T cells, solid tumor regenerative medicine, single cell technology, space-time transcriptomics and multiomics technology, flow cytometry, adeno-associated virus (AAV), gene vector, lentivirus, adenovirus, cell therapy product registration and application, 3D cell culture, organ like culture, biological 3D printer, 3D cell imaging, mRNA vaccine/drug research and development, innovative drug research and development, PD-1/L1 drug, early screening and early diagnosis, tumor metastasis and recurrence monitoring Molecular targeted treatment of tumors, clinical research and disease treatment of exosomes, targeted drug use, genome science and technology led by NGS technology, digital PCR, mass spectrometry, PCR derivative technology, industrialization process of precision medicine, molecular diagnosis, gene therapy, nucleic acid drugs, gene sequencing, liquid biopsy and early screening of tumors, full cycle of tumors, clinical treatment of tumors, genomics, biomarkers, translational medicine, biological products Serum free culture media, reagents, instruments, consumables, CRO, CMO, CDMO, bio information big data, AI auxiliary diagnosis, in vitro diagnosis, antibody, MALBAC technique, Crispr/Cas9 and gene editing technology, laboratory management and control, clinical application and research, tumor drug gene detection, policy supervision, histology big data, industrial cluster booth and forum sponsorship

Scope

Please consult

Costs & Precautions

Please contact the exhibition organizer for confirmation before participating in the exhibition.

Contact

  • Company:Shanghai Shunzhan Exhibition Service Co., Ltd
  • Truename:Wu Tong
  • Mobile:18721130652
  • Address:No. 619, Yingwu Avenue, Hanyang District, Wuhan

Disclaimer

The information on this site comes from the network and related members, and the website has done its duty to review it. Due to the uncontrollability of the process of organizing the exhibition, some of the exhibition information in the station may change the subject matter, Extending or cancelling the event, please exhibitors and visitors must check with each other again before exhibiting! All the exhibitions in this site are not hosted/co-organized or organized, if there are any disputes during the exhibition, please hold the main responsibility of the exhibition organization! QQ Email: 523138820@qq.com WeChat: 523138820 Mobile: 15313206870

HOT

Expo News